Subscribe To
SRRA / Why Sierra Oncology Stock Is On Fire Today
SRRA News
By Invezz
April 13, 2022
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share i more_horizontal
By InvestorPlace
April 13, 2022
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. more_horizontal
By Benzinga
April 13, 2022
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKlin more_horizontal
By Barrons
April 13, 2022
Sierra Oncology Soars After Takeover by Glaxo
The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July. more_horizontal
By Benzinga
April 13, 2022
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate tot more_horizontal
By Pulse2
April 13, 2022
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details. more_horizontal
By Market Watch
April 13, 2022
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed more_horizontal
By Reuters
April 13, 2022
GSK to buy Sierra Oncology for $1.9 billion
Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies more_horizontal
